ImageneBio, Inc.

IMA Nasdaq SEC CIK 1835579
Follow ImageneBio Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$10.2M −34.2% vs same quarter last year
EPS, diluted −$0.63 +85.9% vs same quarter last year
Operating cash flow −$9.1M +23.8% vs same quarter last year
Operating income −$11.8M −60.2% vs same quarter last year
Revenue by quarter
$3.5M
$0
$800K
$0
$0
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25M$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$800K−$45.3M
FY24$3.5M−$36.6M
FY23$9.2M−$68.2M
FY22$15.6M−$68.8M
FY21$31M−$34.1M
FY20$9.2M−$44.3M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−6056.4%−5668.6%
FY24−1057.1%−1044.8%
FY23−823.3%−744.2%
FY22−454%−440.3%
FY21−110.2%−110.1%
FY20−484.2%−481.4%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23−$80.2M
FY22−$75.5M
FY21−$62M
FY20−$38.6M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • ImageneBio
  • Healthcare median
−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearImageneBioHealthcare median
FY25−5668.6%−66.4%
FY24−1044.8%−87%
FY23−744.2%−128.5%
FY22−440.3%−143.6%
FY21−110.1%−137.7%
FY20−481.4%−134.3%
FY19-−125.9%

News

No stories filed under ImageneBio yet - coverage appears here as the news feed clusters it.